What's behind AstraZeneca's latest 8.4% stock pullback?

Traders Union
All News
Financial News
Astrazeneca drops 8.43% today

Highlights

AstraZeneca's phase III trial for Wainua in transthyretin amyloid cardiomyopathy failed, triggering a steep equity decline.
The company secured a $200 million licensing deal with Sino Biopharmaceutical for ex-China rights to a late-phase COPD therapy.
AstraZeneca trades below major moving averages after an 8.4% drop; strong intraday volatility suggests near-term consolidation between GBX10,588 and GBX13,341.

Mixed sentiment as trial miss offsets new licensing and NHS moves

AstraZeneca reported a setback as the phase III CARDIO-TTRansform trial of Wainua (eplontersen) in adults with transthyretin amyloid cardiomyopathy failed to meet its primary objective. This was accompanied by the company's new licensing agreement with Sino Biopharmaceutical involving a $200 million upfront payment and up to $2.1 billion in milestones for ex-China rights to a late-phase COPD treatment. AstraZeneca also neared a deal with England's NHS to broaden access to Enhertu, with the HELIOS rare disease study being terminated early and limited direct impact expected, and disclosed a minor officer share grant.

Anton Kharitonov, expert at Traders Union, views AstraZeneca's sharp 8.43% decline as a confirmation of persistent bearish sentiment. He notes the failure of the Wainua trial adds to structural weakness, especially as the stock sits firmly below all major moving averages. Kharitonov sees little immediate relief despite mixed momentum signals, emphasizing ongoing risk as volatility surges. He remains wary of any short-term bounce, citing the company's disappointing news flow and heavy selling pressure. "Given the negative clinical results and lack of technical support, I see the risks tilting to the downside for AstraZeneca in the near term."

Viktoras Karapetjanc, expert at Traders Union, finds compelling longer-term opportunity despite recent headline setbacks. He points to AstraZeneca's active deal-making and new licensing agreements as signals of strategic strength. Karapetjanc stresses that momentum indicators hint at underlying buyer interest, with upcoming NHS expansions for Enhertu adding to the growth narrative. He believes the recent volatility provides an attractive entry for forward-looking investors. "Short-term volatility is only noise — AstraZeneca’s bullish structure remains intact as it continues to innovate and expand globally."

Jainam Mehta, market strategist, highlights AstraZeneca’s sharp intraday swings as a sign of potential near-term consolidation. He notes that technical levels at GBX13,106 and GBX12,388 will be crucial for direction. Mehta sees opportunity for tactical traders to watch for a breakout above resistance or a breakdown to lower support. "The current volatility band could offer contrarian trades if price reacts strongly at these inflection points."

Technical levels signal seller control with oscillators showing divided momentum

AstraZeneca is trading below its 20-day, 50-day, and 200-day moving averages at GBX13,821, GBX13,731, and GBX13,768, respectively, with the current price at GBX13,040. This configuration signals persistent pressure from sellers across all timeframes, maintaining a bearish medium- and long-term structure. Immediate resistance stands at the near-term ceiling of GBX13,106, while support is at the near-term floor of GBX12,388. Momentum indicators are mixed: MACD reflects ongoing buying momentum, but the ADX shows a selling trend. The RSI and CCI are positioned in neutral-to-bullish zones, Stochastic RSI signals overbought conditions, and BBP shows buyers dominating intraday action despite being overbought. The Awesome Oscillator is neutral and does not confirm the downtrend. AstraZeneca fell GBX1,200 or 8.43% following a sharp downside gap of nearly GBX1,852, with pronounced volatility at 5.80%. The early drop followed by recovery underlines strong intraday swings and potential consolidation, while momentum and oscillators deliver a mixed outlook.

Previously it was reported that AstraZeneca shares came under significant pressure following the failure of a key clinical trial for Wainua (eplontersen), contributing to a persistently bearish outlook. The latest price action and technical configuration strengthen this bearish case, highlighting the importance of monitoring any breakout above GBX13,106 or breakdown below GBX12,388 as potential catalysts for the next directional move.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.